Machine Learning in Multiple Sclerosis
- PMID: 37988527
- Bookshelf ID: NBK597468
- DOI: 10.1007/978-1-0716-3195-9_28
Machine Learning in Multiple Sclerosis
Excerpt
Multiple sclerosis (MS) is characterized by inflammatory activity and neurodegeneration, leading to the accumulation of damage to the central nervous system resulting in the accumulation of disability. MRI depicts an important part of the pathology of this disease and therefore plays a key part in diagnosis and disease monitoring. Still, major challenges exist with regard to the differential diagnosis, adequate monitoring of disease progression, quantification of CNS damage, and prediction of disease progression. Machine learning techniques have been employed in an attempt to overcome these challenges. This chapter aims to give an overview of how machine learning techniques are employed in MS with applications for diagnostic classification, lesion segmentation, improved visualization of relevant brain pathology, characterization of neurodegeneration, and prognostic subtyping.
Copyright 2023, The Author(s).
Sections
- 1. Introduction to MS
- 2. Machine Learning to Aid in the Differential Diagnosis of MS
- 3. Machine Learning for Lesion Segmentation and Quantification
- 4. Machine Learning to Improve Detection of Tissue Properties from Conventional MRI Sequences
- 5. Machine Learning to Characterize Neurodegeneration in MS
- 6. Machine Learning to Predict Disease Progression
- 7. Concluding Remarks
- Acknowledgments
- References
References
-
- Walton C et al (2020) Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler 26:1816–1821. https://doi.org/10.1177/1352458520970841 - DOI - PMC - PubMed
-
- Barkhof F (2002) The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol 15:239–245. https://doi.org/10.1097/00019052-200206000-00003 - DOI - PubMed
-
- (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 45:1277–1285 - PubMed
-
- Jacobs LD et al (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39:285–294. https://doi.org/10.1002/ana.410390304 - DOI - PubMed
-
- Fox RJ et al (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 367:1087–1097. https://doi.org/10.1056/NEJMoa1206328 - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources